Literature DB >> 2827340

Pharmacokinetics of fragmin. A comparative study in the rabbit of its high and low affinity forms for antithrombin.

M Palm1, C Mattsson.   

Abstract

A tritium-labelled low molecular weight heparin fragment with an average molecular weight of 4000-6000 (Fragmin), was fractionated into its high and low affinity forms for antithrombin. The fractions obtained were injected into rabbits, and the plasma half-life (t1/2) volume of distribution (Vd), area under the curve (AUC), total body clearance (TCl) and renal clearance (Clr) were determined. When followed by radioactivity, both the high and low affinity forms of Fragmin as well as Fragmin itself were eliminated from plasma in a biexponential manner. Values for AUC were very low compared to those expected from the given dose. This effect was most pronounced for low affinity-Fragmin demonstrating a significantly higher extravascular distribution of molecules lacking affinity for antithrombin. From radio activity data, it was also demonstrated that the fraction of dose that was eliminated from plasma via non-renal (cellular clearance) mechanisms was higher for heparin (95 per cent) than for Fragmin (77 per cent) after a dose of 100 micrograms/kg. This demonstrates that cellular clearance is of less importance in the plasma elimination of low molecular weight heparin fragment, an effect that may explain their longer plasma half-lifes despite the fact that they are more readily and faster excreated into the urine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2827340     DOI: 10.1016/0049-3848(87)90345-8

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

Review 1.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 2.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

3.  Low-Mr heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme.

Authors:  G Q Liu; G Bengtsson-Olivecrona; P Ostergaard; T Olivecrona
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

Review 4.  Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?

Authors:  Kristian B Johansen; Torben Balchen
Journal:  Exp Hematol Oncol       Date:  2013-08-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.